Q3 2025 EPS Estimates for Hologic, Inc. (NASDAQ:HOLX) Decreased by Leerink Partnrs

Hologic, Inc. (NASDAQ:HOLX) – Stock analysts at Leerink Partnrs decreased their Q3 2025 earnings per share (EPS) estimates for shares of Hologic in a note issued to investors on Monday, October 7th. Leerink Partnrs analyst P. Souda now forecasts that the medical equipment provider will earn $1.09 per share for the quarter, down from their previous forecast of $1.16. The consensus estimate for Hologic’s current full-year earnings is $4.09 per share.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same period last year, the firm earned $0.93 earnings per share. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year.

Several other equities analysts have also recently issued reports on the company. Leerink Partners decreased their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday. Stephens reiterated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $82.00 price target on shares of Hologic in a research note on Friday, August 16th. Citigroup cut shares of Hologic from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. increased their price objective on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 30th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $87.50.

Hologic Stock Performance

NASDAQ HOLX opened at $79.81 on Thursday. Hologic has a 52-week low of $64.02 and a 52-week high of $84.67. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The business’s 50-day moving average price is $81.06 and its 200 day moving average price is $77.57. The firm has a market cap of $18.54 billion, a P/E ratio of 27.15, a P/E/G ratio of 2.89 and a beta of 0.98.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its position in shares of Hologic by 77.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after purchasing an additional 2,753,016 shares in the last quarter. Swedbank AB bought a new position in Hologic during the first quarter worth about $120,827,000. Black Creek Investment Management Inc. increased its stake in Hologic by 60.9% in the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after purchasing an additional 885,524 shares in the last quarter. Mackenzie Financial Corp raised its stake in Hologic by 1,023.3% during the 2nd quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock worth $66,506,000 after buying an additional 815,960 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Hologic during the 2nd quarter worth approximately $39,427,000. Institutional investors own 94.73% of the company’s stock.

Insiders Place Their Bets

In other news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the transaction, the director now owns 45,472 shares in the company, valued at $3,615,024. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares in the company, valued at approximately $3,615,024. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,280 shares of company stock worth $1,469,973 over the last ninety days. 1.75% of the stock is currently owned by company insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.